Life Sciences AISeedWorkflowℹ138 viewsSerinus Biosciences
Serinus Biosciences uses a knowledge-primed AI engine to design cancer combination therapies by mapping how tumor cells evolve treatment resistance and identifying molecules that override resistance escape routes.
Startup snapshot
- Stage
- Seed
- Funding
- Seed
- Status
- published
- Updated
- May 7, 2026
- Views
- 138 views
- Category
- Life Sciences AI
- Website
- serinus.bio
What they're building
Serinus Biosciences uses a knowledge-primed AI engine to design cancer combination therapies by mapping how tumor cells evolve treatment resistance and identifying molecules that override resistance escape routes.
Founders
Maxwell Sherman
Co-founder
Adam Yaari
Co-founder
Foundation model usage
- Architecture pattern
- Agentic loops, Multimodal processing, Embeddings & semantic search
- Model demand
- High intensity
NYC footprint
- NYC office
- 430 E 29th St, New York, NY 10016
Funding
Latest funding: Seed.
AI Lab Fit
Strong fit for multimodal reasoning, biological data retrieval, molecule and protein analysis, structured extraction, and research copilots.
Notes
Serinus Biosciences is tagged workflow based on buyer clarity, repeat workflow activity, public activity, and fit with the AI Atlas map.
Related NYC startups
Output Biosciences is building Large Biological Models, generative AI architectures designed to handle the long, nonlinear, fragmented data of biological systems across molecules, cells, and organisms.
Output Biosciences is building Large Biological Models, generative AI architectures designed to handle the long, nonlinear, fragmented data of biological systems across molecules, cells, and organisms.
Life Sciences AIWorkflowℹ49viewsRecent Activity
Proxima Bio, formerly VantAI, is an AI-native platform for proximity-based drug discovery, mapping protein-protein interactions to design medicines that reshape protein networks rather than inhibit single targets.
Proxima Bio, formerly VantAI, is an AI-native platform for proximity-based drug discovery, mapping protein-protein interactions to design medicines that reshape protein networks rather than inhibit single targets.
Life Sciences AIWorkflowℹ114viewsRecent Activity